The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.
Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...
Additionally, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay – Roche’s immunohistochemistry (IHC) companion diagnostic for identifying ovarian patients eligible for ELAHERE – has been ...
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Leading Hyperscalers and HPC Customers Embrace the Open, Scalable, Standards-Based Veyron V2 Accelerated Compute Platform to Power AI, Data Center, and Emerging Workloads To meet with the Ventana ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback